Accelerated clearance of PEGylated liposomes in rats after repeated injections

被引:269
作者
Ishida, T
Maeda, R
Ichihara, M
Irimura, K
Kiwada, H
机构
[1] Univ Tokushima, Grad Sch Pharmaceut Sci, Dept Pharmacokinet & Biopharmaceut, Tokushima 7708505, Japan
[2] Taisho Pharmaceut Co Ltd, Drug Safety Res Lab, Tokushima 7710194, Japan
关键词
PEGylated liposomes; repeated injection; accelerated clearance effect; polyethylene glycol (PEG);
D O I
10.1016/S0168-3659(02)00462-5
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Polyethylene glycol-modified liposomes (PEGylated liposomes) represent promising carrier systems for therapeutic agents. Herein, we report on a study of the effect of repeated injection of PEGylated liposomes on their pharmacokinetics in rats. The first dose resulted in a reduction in the circulation time and an increase in hepatic accumulation of the second dose in a time-interval of injection-dependent manner. No significant increases in the number of Kupffer cells were detectable, although the liver most likely played an important role in the accelerated clearance. Interestingly, the acceleration in clearance became less pronounced, when the third dose was injected at 4, 7 or 14 days after the second injection (the second dose was given 5 weeks after the first injection). An accelerated clearance was evoked in normal rats by the transfusion of serum from rats that had received PEGylated liposomes 5 days earlier, indicating that humoral serum factor(s) are also involved in causing the accelerated clearance. A complement consumption assay indicated that the complement system is not the factor. In summary, multiple injections of PEGylated liposomes clearly altered their pharmacokinetic behavior in rats. It is likely that cellular immunity (Kupffer cells) and Immoral immunity are required to cause the phenomenon. The results reported here have a considerable impact in and important implications on the clinical application, design and engineering of PEGylated liposomes for use in repeated intravenous administration. (C) 2002 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:35 / 42
页数:8
相关论文
共 20 条
[1]   Liposome targeting in animal models: Problems and opportunities [J].
Allen, TM .
JOURNAL OF LIPOSOME RESEARCH, 1997, 7 (04) :315-329
[2]   PHARMACOKINETICS OF STEALTH VERSUS CONVENTIONAL LIPOSOMES - EFFECT OF DOSE [J].
ALLEN, TM ;
HANSEN, C .
BIOCHIMICA ET BIOPHYSICA ACTA, 1991, 1068 (02) :133-141
[3]  
BARTLETT GR, 1959, J BIOL CHEM, V234, P466
[4]  
Dams ETM, 2000, J PHARMACOL EXP THER, V292, P1071
[5]  
de Menezes DEL, 1998, CANCER RES, V58, P3320
[6]  
Devine DV, 1997, CRIT REV THER DRUG, V14, P105
[7]   Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer [J].
Gordon, AN ;
Granai, CO ;
Rose, PG ;
Hainsworth, J ;
Lopez, A ;
Weissman, C ;
Rosales, R ;
Sharpington, T .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (17) :3093-3100
[8]   A phase II study of pegylated liposomal doxorubicin for treatment of advanced hepatocellular carcinoma [J].
Halm, U ;
Etzrodt, G ;
Schiefke, I ;
Schmidt, F ;
Witzigmann, H ;
Mössner, J ;
Berr, F .
ANNALS OF ONCOLOGY, 2000, 11 (01) :113-114
[9]   Identification of proteins mediating clearance of liposomes using a liver perfusion system [J].
Harashima, H ;
Matsuo, H ;
Kiwada, H .
ADVANCED DRUG DELIVERY REVIEWS, 1998, 32 (1-2) :61-79
[10]   KINETIC-ANALYSIS OF AUC-DEPENDENT SATURABLE CLEARANCE OF LIPOSOMES - MATHEMATICAL-DESCRIPTION OF AUC DEPENDENCY [J].
HARASHIMA, H ;
YAMANE, C ;
KUME, Y ;
KIWADA, H .
JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1993, 21 (03) :299-308